Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MM-121 with Paclitaxel in Neoadjuvant HER2-negative Breast Cancer
NCT01421472Phase 2Completed
- Sponsor
- Merrimack Pharmaceuticals
- Start
- Aug 2011
- Primary completion
- Dec 2013
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of seribantumab in breast cancer (2 arms), sponsored by Merrimack Pharmaceuticals. Primary endpoint: Pathologic Complete Response. Started Aug 2011; status: completed.
02
Drugs
seribantumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01421472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01421472.